Keyword: Polaris Partners
BlackThorn Therapeutics raised $76 million to push targeted treatments for mood disorders into phase 2 studies.
Ajax Health's raise will be used to help identify potentially disruptive startups toward the ultimate goal of achieving an exit within four years.
Dewpoint Therapeutics will develop a drug platform targeting biomolecular condensates, an “understudied” type of organelle found inside cells.
After having invested in Morphic Therapeutic’s A and B rounds, AbbVie is pulling the trigger on an R&D deal.
Glympse Bio, a startup that builds bioengineered in vivo sensors for disease, has emerged from stealth with a $22 million series A round.
Lyra Therapeutics' series B will move its lead program, a rhinosinusitis treatment based on its transmucosal drug delivery platform, into phase 2.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
Boston startup Jnana Therapeutics wants to unlock the potential of a class of membrane proteins it calls the cell’s "metabolic gates."
The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.